Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1564-2022Class II

NUCLISENS easyMAG Magnetic Silica, REF 280133, 24 x 1.2mL bottles/kit

bioMerieux, Inc. / initiated 2022-07-20 / Open, Classified / root cause: manufacturing process

bioMerieux, Inc. began a recall of NUCLISENS easyMAG Magnetic Silica, REF 280133, 24 x 1.2mL bottles/kit on . FDA classified it as Class II and gives the reason as "There is a potential of no result leading to possible delayed result due to contamination of extraction reagents". As of , the recall status on record is Open, Classified, and MDM tags the root cause as manufacturing process.

Recall record

Recall number
Z-1564-2022
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
bioMerieux, Inc.
Product
NUCLISENS easyMAG Magnetic Silica, REF 280133, 24 x 1.2mL bottles/kit.
Product code
PPM General Purpose Reagent
Reason for recall
There is a potential of no result leading to possible delayed result due to contamination of extraction reagents.
Root cause tag
manufacturing process
FDA root cause
Nonconforming Material/Component
Action
The recalling firm issued undated letters with a reference number of FSCA#5690 via overnight mail on 7/20/2022. The letter explained the issue and instructed the customers to distribute the information to all appropriate personnel in their laboratory and forward the information to all parties that may use the product, including others to whom the customer may have transferred the product. They are informed they can continue to use the impacted lots of the NUCLISENS Magnetic Silica Ref 280133 listed in Table 1 except for bacterial nucleic acid detection applications, especially Legionella spp, and other applications such as 16S rDNA, 23S rDNA. The recalling firm confirms that all applications for which the negative controls are valid can be safely performed. If the customer is encountering invalid negative controls, they are to stop using it and discard the impacted lot and contact the bioMerieux representative to order lots not concerned by the issue. Based on benefit/risk analysis and to avoid product backorder, the customer is informed that for a short period of time, they may receive some of the lots listed in Table 1 of the letter with an insert that will contain the same information and actions required as previously mentioned. An Acknowledgement Form was enclosed for return to confirm receipt of the notice. The letter listed all lot numbers globally distributed, but the customers in the U.S. only received lot numbers Z012MK1MS, Z012ML1MS, Z012NB1MS, and Z013AL1MS. The U.S. customers could receive other lots listed in the letter at a later time.
Quantity in commerce
1,301 kits
Distribution
Distribution was made to AR, AZ, CA, CT, FL, IL, IN, KS, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NY, OH, OR, PA, TN, TX, and VA. There was no government/military distribution.
Product codes and lots
Lot numbers distributed in the U.S.: Z012MK1MS, exp. 28-NOV-2022; Z012ML1MS, exp. 28-NOV-2022; Z012NB1MS, exp. 28-DEC-2022; Z013AL1MS, exp. 28-JAN-2023. UDI: 03573026139339.

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1564-2022
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1564-2022Class IIOngoingVoluntary: Firm initiated